Page 294 - 2022_01-Haematologica-web

Letters to the Editor
Center, New York, NY, USA; 4Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; 5Department of Hematology, Skane University Hospital Malmö/Lund, Malmö/Lund, Sweden; 6Department of Chemical Biology, Sloan Kettering Institute, New York, NY, USA and 7Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
*UAS and SR contributed equally as co-first authors #SYK and OL contributed equally as co-senior authors Correspondence:
URVI A. SHAH - shahu@mskcc.org doi:10.3324/haematol.2021.278772
Received: March 16, 2021.
Accepted: August 26, 2021.
Pre-published: September 2, 2021.
Disclosures: UAS has received research funding from Celgene/Bristol Myers Squibb and Janssen, to her institution and
honorariums for continuing medical education activity from the Physicians Education Resource, all outside of the submitted work.
M.B. reports the following, all outside of the submitted work: research funding from Takeda; member of independent data monitoring commit- tee for Mundipharma; lecture honoraria from Roche, Pfizer and BMS, Grant committee work for Incyte. COL has received grant support from: LLS, Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, NIH, FDA, MMRF, IMF, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex. Presented in abstract form at the 62nd annual meeting of the American Society of Hematology, 6 December 2020.
Contributions: all authors participated in the writing and review of the manuscript. Additionally UAS and SR designed the study and per- formed data analysis; AD performed data analysis and designed sta- tistical methods; MB and IT curated the data and were involved in study design conception; YD, SP, MH, CT, HH, NK, AL, and SM were involved in study design conception; SYK and COL curated the data, designed the study, and supervised the research project.
Acknowledgments: the authors would like to thank Hannah Rice, BA, ELS for editorial assistance.
Funding: this research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 (UAS) and supported by grants from Swedish Cancer Society (MB), Parker Institute of Cancer Immunotherapy Career Development Award (YD, UAS), International Myeloma Society Career Development Award, Paula
and Rodger Riney Foundation, American Society of Hematology Clinical Research Training Institute Award and TREC Training Workshop R25CA203650 (PI: Melinda Irwin) (UAS).
Data sharing statement: The data included in study is built on multi- ple population-based registries including the medical records of Swedish citizens. Although the data has been made unidentifiable before analy- sis, ethical board approval does not permit data sharing.
References
1. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non-Hodgkin's lym- phoma: a meta-analysis of observational studies. Diabetes Care. 2008;31(12):2391-2397.
2. Pearson-Stuttard J, Bennett J, Cheng YJ, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165-173.
3.Gong IY, Cheung MC, Read S, Na Y, Lega IC, Lipscombe LL. Association between diabetes and haematological malignancies: a population-based study. Diabetologia. 2021;64(3):540-551.
4. Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of can- cer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098-1106.
5. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845-4850.
6. Fortuny J, Benavente Y, Bosch R, Garcia-Villanueva M, de Sevilla AF, de Sanjose S. Type 2 diabetes mellitus, its treatment and risk for lym- phoma. Eur J Cancer. 2005;41(12):1782-1787.
7. Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non- Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica. 2008;93(6):842-850.
8. Kristinsson SY, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O. Risk of lymphoproliferative disorders among first- degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 112(8):3052-6.
9. Yan P, Wang Y, Yu X, Liu Y, Zhang ZJ. Maternal diabetes and risk of childhood malignancies in the offspring: a systematic review and meta-analysis of observational studies. Acta Diabetol. 2021; 58(2):153-168.
10. Chang SH, Luo S, O'Brian KK, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mel- litus: a population-based retrospective cohort study. Lancet Haematol. 2015;2(1):e30-36.
11. Ueberberg S, Nauck MA, Uhl W, et al. Islet amyloid in patients with diabetes due to exocrine pancreatic disorders, type 2 diabetes, and nondiabetic patients. J Clin Endocrinol Metab. 2020;105(8):dgaa176.
12. Diez R, Madero M, Gamba G, Soriano J, Soto V. Renal AA amyloi- dosis in patients with type 2 diabetes mellitus. Nephron Extra. 2014; 4(2):119-126.
13. Omtvedt LA, Bailey D, Renouf DV, et al. Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid. 2000;7(4):227-244.
14. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15(6):346-366.
15. Huang Y, Cai X, Qiu M, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261-2269.
286
haematologica | 2022; 107(1)